Cannabis Law Report

OCTOBER 2, 2021

The results of our successful pivotal Phase 3 clinical trial were recently published in Nature Medicine and profiled on the front page of The New York Times. The right candidate will have a passion for clinical research in novel therapeutics and a proven track record of regulatory affairs experience. Key Responsibilities.

Clinical Trials 52

Clinical Trials Research and Development Compliance Compliance 52

Cannabis Law Report

AUGUST 21, 2019

In November 2018, the legal status of cannabis was changed to allow specialist clinicians to legally prescribe cannabis-derived medicinal products to patients with an exceptional clinical need, following a high-profile media campaign. The final guideline is expected to be published in November 2019.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. Team leadership : mentor European study teams in overall regulatory strategy and compliance to enable future patient access expeditiously.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Cannabis Law Report

MAY 31, 2022

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

AUGUST 19, 2021

. – ‘No definitive evidence’ – British charity Versus Arthritis recommends patients contemplating CBD should consult their doctor beforehand, and also wants more work done to understand its impact.

Cannabinoids 105

Cannabinoids Seed-To-Sale Clinical Trials CBD 105

Cannabis Law Report

JANUARY 14, 2022

On December 10 , last year, the bill, which aimed to open prescribing to thousands or UK patients was ‘talked-out’ by the ruling Conservative Party MPs. THE Member of Parliament sponsoring the Medical Cannabis Access Bill in the House of Commons today has acknowledged it is set to fail due to lack of political support.

Access 52

Access Clinical Trials Patients Business 52

Cannabis Law Report

JULY 14, 2021

ImmunoFlex” ), today announced that it has completed and analyzed its clinical trial of 21 patients, aged 60 to 70 years. In one particular group, all patients showed consistent results across multiple genomic analyses. federal law.

Research and Development 81

Research and Development Clinical Trials Events Treatment 81

Cannabis Law Report

JANUARY 9, 2019

Tindall also hope to commence the clinical trials with Vanuatu for diabetes treatment. Phoenix are conducting short-term CBD oil studies with local patients at the country’s general hospital. It’s important to us to run local trials, so we are not relying on evidence from elsewhere,” Tindall said. “It Photo: Google Maps.

Therapy 85

Therapy Clinical Trials Treatment Medicine 85

Cannabis Law Report

NOVEMBER 13, 2019

Denmark is already leading the way by launching a Big Pharma modelled 4-year medical marijuana trial in early 2018, following a unanimous vote in Parliament. Coupled with transit time and testing in the EU, delays could impact the shelf-life of product patients will receive,” he said. Arundati Dandapani. Founder and CEO, . Generation1.ca.

Clinical Trials 78

Clinical Trials Research and Development Cultivation Patients 78

Cannabis Law Report

OCTOBER 10, 2021

As a think tank we develop new ideas and concepts for providing medical cannabis to patients both in Germany and Europe. Cantourage is an innovative company ensuring that patients are able to access the newest medicinal products based on cannabis. YOUR PROFILE: Bachelor’s degree in life science, relevant scientific field required (e.g.

Clinical Trials 52

Clinical Trials Therapy Medicine Pharmaceutical 52

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Physician’s Prescription: Patients must obtain a prescription from a qualified physician registered with the TCUP.

Law 52

Law Clinical Trials Dispensary Programs 52

Cannabis Law Report

OCTOBER 26, 2019

ii Non-clinical studiesAlthough the use of animals in research is separately regulated by each state and territory, all require compliance with the Australian Code for the Care and Use of Animals for Scientific Purposes (Animal Code). One such circumstance is a clinical trial. medical practitioner), an organisation (e.g.,

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. Exploring CBD for Medical Use As interest in CBD grows, researchers are continuously exploring its potential applications in the medical field.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

MMJ Recs

JULY 3, 2024

This variability can pose challenges for medical marijuana patients seeking consistent access to safe and effective CBD products, as well as for businesses aiming to comply with a patchwork of state laws. For more information, read our post “ Understanding the Endocannabinoid System: A Guide for Medical Marijuana Patients ”.

CBD 52

CBD Research and Development Clinical Trials THC 52

Cannabis Law Report

NOVEMBER 29, 2019

While the market for medical cannabis is already well developed in some EU member states, only EU-wide standards can ensure patients have the same across Europe. Different legislation across EU countries on prescribing cannabis-based medicines can hinder patients’ access to their treatment when they travel abroad, EUMCA said.

Medicine 45

Medicine Clinical Trials Treatment Access 45

Cannabis Law Report

DECEMBER 9, 2021

. “The FDA is supportive of our plans to develop regulated devices that would allow the use of novel analyses of multimodal data to capture, model, and map outputs that, if cleared, could be useful to clinicians and patients in the delivery of psychedelic and other perception-altering substances.”

Research and Development 52

Research and Development Clinical Trials Therapy Medicine 52

Cannabis Law Report

JANUARY 24, 2022

Accomplished leader to oversee Goldfinch Bio’s clinical function to advance precision medicines for people living with kidney disease. Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. CAMBRIDGE, Mass.–(BUSINESS

Clinical Trials 40

Clinical Trials Research and Development Data Medicine 40

Cannabis Law Report

AUGUST 18, 2022

The firm’s deep expertise in pharmaceutical sciences, FDA regulatory compliance and pharmaceutical product liability litigation and risk management enables it to address complex legal hurdles faced by stakeholders seeking to research, develop, invest in and bring-to-market psychedelic therapies. . ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

MARCH 7, 2019

Switzerland’s government will allow 5,000 citizens to use cannabis legally, as part of a country-wide clinical trial. Those who sign up to the trial would receive a small amount of cannabis each month, to smoke or eat.

Clinical Trials 56

Clinical Trials Research and Development Decriminalization Environment 56

Cannabis Law Report

JANUARY 19, 2022

GMP psilocybin previously manufactured by Psygen personnel in collaboration with a licensed dealer using Psygen’s methods has already been used in clinical trials for development of therapeutic products. “A primary application for psychedelics is to support psychotherapy for treatment of mental health conditions.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Conditions 52

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. Licensed wholesalers will be able to import larger quantities of cannabis-based products, and hold supplies for future use by patients with prescriptions, according to a government release.

Medicine 45

Medicine Research and Development Clinical Trials Patients 45

Cannabis Law Report

MARCH 29, 2022

Former Moderna Vice President and Managing Director for North America recruited to prepare MAPS PBC for patient access and commercialization of the first psychedelic-assisted therapy anticipated to be approved by the FDA. Dawn Lundin, M.S. , has joined MAPS PBC as Head of Global Quality Management Systems.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Access 52

Cannabis Law Report

JULY 4, 2021

Clinical trials across the EU have also shown CBD oils and other hemp products to have a potential range of benefits. This is true if patients have the necessary medical conditions and if other treatments have not been effective. When used by humans, CBD shows no possibility of abuse or dependence. Now we come to CBD.

THC 81

THC CBD Legalization Oil 81

Cannabis Law Report

JULY 23, 2019

LGC and its investors will benefit from a substantial competitive advantage through their knowledge and clinical trial capacity and its capacity to handle the regulatory compliance process for pharmaceuticals and food products,” said Mazen Haddad, CEO of LGC. Accelerate Freia’s growth and expansion.

Pharmaceutical 45

Pharmaceutical Seed-To-Sale Compliance Clinical Trials 45

Cannabis Law Report

OCTOBER 29, 2021

The highlights for the quarter are: As previously disclosed, on September 7, 2021, the Company announced the completion of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”) based investigational new drug, IGC-AD1, intended to alleviate certain symptoms of individuals who have Alzheimer’s disease.

Clinical Trials 40

Clinical Trials Research and Development Data Business 40

Cannabis Law Report

JUNE 1, 2021

As we prepare for a potential world-class launch of Vicineum, I strongly believe that these leaders will not only bring diverse and invaluable expertise to our team but will also drive the Company to continue executing our mission to save and improve the lives of patients with cancer.”. CAMBRIDGE, Mass.–(BUSINESS

Research and Development 51

Research and Development Treatment Pharmaceutical Patients 51

Cannabis Law Report

JULY 15, 2019

Law 33/2018 set the framework for the regulation of the use of cannabis-based medicinal products, preparations and substances that would effectively allow Portuguese patients to access medical cannabis What really has changed during the last year? July 18 marks the first anniversary of the Portuguese medical cannabis law.

Medicine 40

Medicine Clinical Trials Patients Access 40

Cannabis Law Report

JUNE 9, 2022

The bill would expand patients’ access to the necessary treatment for more than 50 conditions, including cancer and post-traumatic stress disorder (PTSD), neurological diseases, and chronic pain of neuropathic origin. “ 8) Article 17 shall be worded as follows: Article 17.

Seed-To-Sale 52

Seed-To-Sale Legalization Cultivation Medicine 52

Cannabis Law Report

JUNE 4, 2021

He practiced as a British Physiotherapist for over fifteen years, running clinics that specialized in integrative pain management and injury rehabilitation, treating over 40,000 patients. We already see products with Delta 8-THC submitted at the state compliance level in California.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

Cannabis Law Report

DECEMBER 21, 2019

Autism is a very serious health condition that affects patients’ communication and social interaction skills thus making the development and maintenance of a social relationship very difficult. Reports gathered show that the behavioral patterns patients show are more repetitive than erratic.

Research and Development 45

Research and Development CBD Conditions Therapy 45

Cannabis Law Report

FEBRUARY 28, 2020

Similarly, it is also flunking its responsibility to patients and their families who require medicinal cannabis to live normal lives. Most evidence leads us to the conclusion the Home Office changes of November 2018 did nothing to improve the chances of patient access to medicinal cannabis. From bad to worse.

Law 59

Law Research and Development Recreational Cannabis 59

MMJ Recs

DECEMBER 22, 2023

Public discourse became more nuanced, with patients and advocacy groups championing the cause of medical marijuana as a legitimate and effective treatment option. Another influential factor is the growing emphasis on individual autonomy and patient choice in healthcare.

Marijuana 52

Marijuana Chronic Pain Advocacy Research and Development 52

Cannabis Law Report

DECEMBER 21, 2021

Facilitating workforce proof of health compliance data, Dalrada Health’s CLIA-certified laboratory provides on-site concierge services and holds national capability. Payal Keswarpu, presented cerVIA™ clinical study results at the 17th World Congress for Cervical Pathology and Colposcopy before 42 participating countries.

Research and Development 40

Research and Development Supply Chain Data Business 40

Cannabis Law Report

JULY 21, 2022

Patient safety concerns uncovered during an ongoing federal review have led to the suspension of one of two clinical trials for MDMA-assisted psychotherapy currently underway in Canada. The report card also says that medical care for the patients involved was happening without supervision from a qualified investigator.

Safety 52

Safety Patients Clinical Trials Data 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. Clinical Trials and Human Subject Protections. Here are the top five considerations: 1.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

JUNE 3, 2022

Legal Counsel (life sciences) clinical, regulatory, licensing New York Reporting to General Counsel, the Legal Counsel (life sciences) will be responsible for providing legal support and advice regarding all COMPASS clinical, regulatory and licensing matters. Manage compliance matters handled by outside counsel and consultants.

Legalization 59

Legalization Clinical Trials Compliance Compliance 59

Cannabis Law Report

MARCH 1, 2022

Legal Counsel (life sciences) clinical, regulatory, licensing New York Reporting to General Counsel, the Legal Counsel (life sciences) will be responsible for providing legal support and advice regarding all COMPASS clinical, regulatory and licensing matters. Manage compliance matters handled by outside counsel and consultants.

Legalization 52

Legalization Clinical Trials Compliance Compliance 52